Cohance Lifesciences Limited
All news and filings related to Cohance Lifesciences Limited.
View all news & filings- Low impact
Cohance Lifesciences 8th AGM: All Ordinary Resolutions Passed with Overwhelming Majority
Cohance Lifesciences Limited held its 8th AGM on September 17, 2026. All three ordinary resolutions, including the adoption of standalone and consolidated financial statements and the reappointment of Director Ms. Shweta Jalan, were passed with overwhelming majority.
Read the summary - Low impact
Cohance Lifesciences to Attend JP Morgan India Conference and Roadshow
Cohance Lifesciences Limited will participate in investor meetings. Management will attend the JP Morgan India Conference in Mumbai on September 22, 2026, followed by the JP Morgan Roadshow in Hyderabad on September 24, 2026. No unpublished price-sensitive information will be shared.
Read the summary - Medium impact
Cohance Lifesciences Completes USFDA Inspection with 4 Observations
Cohance Lifesciences Limited's formulation plant in Shamshabad, Telangana, underwent a USFDA inspection from August 27 to September 4, 2026. The inspection concluded with four observations noted on a Form FDA 483. The company is implementing corrective actions and will submit its response.
Read the summary - Medium impact
Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy
Cohance Lifesciences will invest USD 13 million (₹108.5 crore) in NJ Bio and USD 5 million (₹41.75 crore) in Aruka Bio to advance its ADC strategy. Ownership in NJ Bio will increase to 67.3%. Aruka Bio will become a direct subsidiary, owned 65% by Cohance. Transactions are expected to complete by September 2026.
Read the summary - High impact
Cohance Lifesciences Boosts ADC Strategy with $18M Investment in NJ Bio and Aruka Bio
Cohance Lifesciences is investing USD 13 million in its subsidiary NJ Bio, Inc. to increase its stake to 67.3%. Additionally, it is investing USD 5 million in Aruka Bio, Inc., acquiring approximately 65% ownership. Both transactions are expected to close by September 2026 and are funded by internal accruals.
Read the summary - Low impact
Cohance Lifesciences to attend Ashwamedh - Elara India Dialogue 2026 on Sept 1
Cohance Lifesciences Limited will participate in the Ashwamedh - Elara India Dialogue 2026 conference in Mumbai on September 1, 2026. The event includes group and one-on-one meetings with analysts and institutional investors.
Read the summary - Low impact
Cohance Lifesciences Announces 8th AGM on September 17, 2026, with E-voting Facility
Cohance Lifesciences Limited will hold its 8th Annual General Meeting on September 17, 2026. The company has provided a remote e-voting facility from September 14 to September 16, 2026. The cut-off date for e-voting eligibility is September 10, 2026.
Read the summary - Low impact
Cohance Lifesciences Submits BRSR Report for FY 2025-26
Cohance Lifesciences Limited has submitted its BRSR for FY 2025-26. The company aims for Net Zero emissions by 2050, 15% energy reduction by 2033, and 50%+ renewable energy by 2033. It also targets a 25% reduction in water usage and 15% in waste generation by 2033, with a goal of 15% gender diversity by 2033.
Read the summary - Medium impact
Cohance Lifesciences Releases Integrated Annual Report FY25-26 and AGM Notice
Cohance Lifesciences has released its Integrated Annual Report for FY25-26, including the BRSR and AGM notice. The company reported consolidated revenue of ₹22.68 billion and adjusted EBITDA of ₹4.8 billion for FY26. Two customer molecules have entered commercial supply, with two more expected soon.
Read the summary - Low impact
Cohance Lifesciences to hold 8th AGM on Sep 17, 2026; E-voting from Sep 14-16
Cohance Lifesciences Limited will hold its 8th Annual General Meeting on September 17, 2026. The meeting will include the adoption of financial statements for FY26 and consider the reappointment of Director Ms. Shweta Jalan. E-voting will be open from September 14 to September 16, 2026.
Read the summary - Low impact
Cohance Lifesciences Withdraws CRISIL Ratings on Certain Facilities
Cohance Lifesciences has requested the withdrawal of its CRISIL credit ratings for certain lower-limit facilities, stating they are covered by India Ratings. The company confirmed no impact on existing facilities. CRISIL noted the withdrawal was at the company's request and cited 'issuer not cooperating' in its rationale for previously downgraded ratings on ₹72.5 crore facilities.
Read the summary - Medium impact
Cohance Lifesciences Reports Q1 FY27 Unaudited Financial Results
Cohance Lifesciences reported unaudited Q1 FY27 results. Standalone income was ₹359.89 crore, with net profit at ₹1.41 crore. Consolidated income was ₹422.26 crore, with net profit at ₹46.40 crore. The Board approved the results on August 4, 2026.
Read the summary - Low impact
Cohance Lifesciences Releases Audio Recording of Q1 FY27 Earnings Call
Cohance Lifesciences Limited has released the audio recording of its conference call for the quarter ended 30 June 2026. The call took place on 5 August 2026, and the recording is available on the company's website.
Read the summary - Medium impact
Cohance Lifesciences Receives 5 Observations from USFDA Inspection at Hyderabad Facility
Cohance Lifesciences' Hyderabad facility underwent a USFDA inspection from July 27 to August 5, 2026. The company received Form FDA 483 with five observations, none related to data integrity. Cohance is preparing a response with corrective actions for timely resolution.
Read the summary - Medium impact
Cohance Lifesciences Q1 FY27 Results: Revenue Declines 23.1% YoY Amidst Strategic Realignment
Cohance Lifesciences reported Q1 FY27 revenue of INR 4,223 million, a 23.1% YoY decline. Adjusted EBITDA was INR 92 million (2.2% margin). The company expects growth to return in H2 FY27, driven by Pharma CDMO recovery and Sapala's performance. Free cash flow was INR 1,063 million, with cash reserves at INR 4,589 million. Strategic focus on integrating Sapala's nucleic acid business.
Read the summary - Medium impact
Cohance Lifesciences Q1FY27 Revenue ₹422.3 crore, Down 23.1% YoY
Cohance Lifesciences reported Q1FY27 revenue of ₹422.3 crore, down 23.1% YoY. Adjusted EBITDA was ₹9.2 crore. The company expects improvement in Q2 and a return to growth in H2 FY27. Strategic priorities include integrating the nucleic-acid business and repositioning Agrochemicals. Consolidated net cash stood at ₹251.2 crore.
Read the summary - Medium impact
Cohance Lifesciences Q1 FY27 Results: Revenue Down 23.1% YoY to ₹422.3 Crore; AGM on Sep 17
Cohance Lifesciences reported Q1 FY27 consolidated revenue of ₹422.3 crore, down 23.1% YoY. Adjusted EBITDA was ₹9.2 crore. The company approved reorganization at subsidiary Sapala Organics and will hold its 8th AGM on September 17, 2026. Management expects Q2 improvement and H2 growth.
Read the summary - Low impact
Cohance Lifesciences Approves ESOP 2026 Grant, Allots 30,190 Shares
Cohance Lifesciences approved ESOP 2026 with up to 1,97,48,317 options and ESOP 2023 with 1,74,843 options. 30,190 shares were allotted upon exercise. The ESOP 2026 exercise price is at least ₹325 or at a 20% discount to market price. 1,87,703 ESOP 2023 grants were cancelled.
Read the summary - Low impact
Cohance Lifesciences Schedules Q1 FY27 Results Conference Call for August 5, 2026
Cohance Lifesciences will host a conference call on August 5, 2026, at 6:30 PM IST to discuss its Q1 FY27 financial results. The results will be announced earlier the same day. Investors and analysts can join the call for management discussion and Q&A.
Read the summary - Low impact
Cohance Lifesciences Clarifies Financial Results Filing with NSE
Cohance Lifesciences Limited submitted revised financial results in XBRL format on 17 July 2026, following a clarification request from NSE on 10 July 2026 regarding earlier submissions.
Read the summary - Low impact
Cohance Lifesciences: Promoters Declare No New Share Encumbrances
Cohance Lifesciences promoters, Berhyanda Limited and associated entities, declared on April 7, 2026, that no new share encumbrances have been made. This declaration is in compliance with SEBI Takeover Regulations, confirming no additional pledges beyond those disclosed in FY2025-26.
Read the summary - Medium impact
Cohance Lifesciences: CFO Himanshu Agarwal Resigns, Last Day Sept 13, 2026
Mr. Himanshu Agarwal, Whole-time Director and CFO of Cohance Lifesciences, has resigned to pursue external opportunities. His last day at the company will be September 13, 2026. The resignation is effective from the close of business hours on this date.
Read the summary - Medium impact
Cohance Lifesciences Shareholders Approve Key Resolutions: Chairman Appointment, Remuneration, and ESOPs
Shareholders of Cohance Lifesciences approved the appointment of Mr. Umang Vohra as Chairman and Group CEO, along with his remuneration exceeding prescribed limits. Key approvals also included the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' and its extension to subsidiaries, as well as a 1% stock option grant limit. The postal ballot results were announced on June 14, 2026.
Read the summary - Low impact
Cohance Lifesciences to Attend Citi India & ICICI Securities Investor Conferences
Cohance Lifesciences Limited will participate in the Citi India Conference on June 5, 2026, and the ICICI Securities India Investor Conference on June 9, 2026. Both events are scheduled to take place in Mumbai. No unpublished price-sensitive information will be disclosed during these meetings.
Read the summary - Low impact
Cohance Lifesciences to Attend Multiple Investor Conferences in May-June 2026
Cohance Lifesciences will attend multiple investor conferences and tours in May and June 2026. Key events include the 360 ONE Capital conference on May 29, BofA Healthcare Tour on June 4, and Goldman Sachs Tour on June 11. Schedule is subject to change.
Read the summary - Medium impact
Cohance Lifesciences Q4 & FY26 Earnings Call Transcript Released
Cohance Lifesciences released its Q4 & FY26 earnings call transcript. The Pharma CDMO business reported FY26 revenue of ₹8.89 billion (approx. ₹889 crore), API Plus ₹10.88 billion (approx. ₹1088 crore), and Specialty Chemicals ₹2.913 billion (approx. ₹291.3 crore). Consolidated revenue declined 13% to ₹22.68 billion (approx. ₹2268 crore). Q1 FY27 is expected to be weak, with recovery anticipated from H2 FY27.
Read the summary - Low impact
Cohance Lifesciences Announces Postal Ballot Notice for Member Approval
Cohance Lifesciences is conducting a postal ballot for member approval on resolutions. E-voting is open from May 15 to June 13, 2026. Results will be announced by June 15, 2026. The notice was dispatched on May 14, 2026.
Read the summary - Medium impact
Cohance Lifesciences Seeks Shareholder Approval for Key Appointments and ESOP Plan
Cohance Lifesciences is seeking shareholder approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO, along with his remuneration. Shareholders will also vote on the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026', its extension to subsidiaries, and grant of options. E-voting runs from May 15 to June 13, 2026.
Read the summary - Low impact
Cohance Lifesciences Announces Participation in Investor Conferences in May 2026
Cohance Lifesciences will participate in Citi's 2026 Pan-Asia Investor Conference (Virtual) in Singapore from May 18-20, 2026, and B&K’s 16th Annual Investor Conference in Mumbai on May 27, 2026. The company confirms that no unpublished price-sensitive information will be disclosed during these interactions. Meeting schedules are subject to change.
Read the summary - Medium impact
Cohance Lifesciences Q4FY26 Results: Revenue at ₹2030.50 Cr, Net Profit ₹343.10 Cr
Cohance Lifesciences reported Q4FY26 results with standalone revenue at ₹567.55 Cr and net profit of ₹34.56 Cr. Consolidated revenue stood at ₹619.12 Cr with net profit of ₹8.31 Cr. Full-year standalone revenue was ₹2030.50 Cr and net profit ₹228.71 Cr. Consolidated full-year revenue was ₹2268.55 Cr and net profit ₹150.12 Cr.
Read the summary - Low impact
Cohance Lifesciences Releases Audio Recording of Q4 FY26 Earnings Call
Cohance Lifesciences has released the audio recording of its conference call for the quarter and year ended March 31, 2026. The call was held on May 12, 2026, and the recording is available on the company's website.
Read the summary - Medium impact
Cohance Lifesciences FY26 Results: Revenue at ₹22.68 Bn, Adjusted EBITDA at ₹4.8 Bn
Cohance Lifesciences reported FY26 revenue of ₹22.68 Bn and Adjusted EBITDA of ₹4.8 Bn. Q4FY26 revenue was ₹6.19 Bn. The company anticipates a recovery from 2HFY27, with Q1FY27 expected to be the low point. Free cash flow for FY26 was ₹1.73 Bn.
Read the summary - Medium impact
Cohance Lifesciences Reports Audited FY26 Financial Results and Approves KMP Revisions
Cohance Lifesciences announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Revenue from operations for FY26 stood at ₹2,030.50 crore (standalone) and ₹2,268.55 crore (consolidated). Net profit after tax for FY26 was ₹228.71 crore (standalone) and ₹150.12 crore (consolidated). The company also revised its authorized Key Managerial Personnel for disclosures.
Read the summary - Low impact
Cohance Lifesciences Schedules Q4 & FY26 Results Conference Call for May 12
Cohance Lifesciences will host an investor and analyst conference call on May 12, 2026, at 6:30 PM IST. The call will discuss the company's audited financial results for Q4 & FY26, which will be declared earlier the same day. Pre-registration is available.
Read the summary - Low impact
Cohance Lifesciences Clarifies Price Movement, No Undisclosed Material Information
Cohance Lifesciences Limited clarified its stock price movement, stating no undisclosed material information exists. The company referenced its board meeting outcome disclosed on April 27, 2026. This clarification addresses queries from BSE and NSE.
Read the summary - Medium impact
Cohance Lifesciences Appoints Mr. Umang Vohra as Chairman and Group CEO
Cohance Lifesciences Limited has appointed Mr. Umang Vohra as Chairman and Group CEO. Mr. Vohra has over 30 years of experience, including leadership roles at Dr. Reddy's Laboratories and Cipla Limited. This appointment follows a board meeting held on April 27, 2026.
Read the summary - High impact
Umang Vohra, Former Cipla CEO, Appointed Executive Chairman & Group CEO of Cohance Lifesciences
Umang Vohra, former Cipla CEO, appointed Executive Chairman & Group CEO of Cohance Lifesciences. He will lead the company's transformation and growth. Mr. Vohra's appointment is effective May 1, 2026, as Executive Chairman and May 20, 2026, as Group CEO. He succeeds Vivek Sharma, who will serve as an advisor.
Read the summary - Medium impact
Cohance Lifesciences Appoints Umang Vohra as Chairman & Group CEO, Notes Resignation of Vivek Sharma
Cohance Lifesciences appointed Umang Vohra as Chairman and Group CEO from May 1, 2026. Vivek Sharma resigned as Executive Chairman and Director, effective April 30, 2026, and will serve as Special Advisor for nine months. The company also approved an Employee Stock Option Plan 2026, offering 25,918,613 options.
Read the summary - Low impact
Cohance Lifesciences Clarifies Volume Surge, Cites Market Driven Factors
Cohance Lifesciences Limited clarified to the NSE that the recent increase in its share trading volume is market-driven and not due to any undisclosed material information. The company confirmed compliance with SEBI regulations regarding disclosures.
Read the summary - Low impact
Cohance Lifesciences Files SEBI Reg 74(5) Certificate for Q4 FY26
Cohance Lifesciences Limited has submitted its quarterly certificate under SEBI Regulation 74(5) for the period ending March 31, 2026. This is a routine compliance filing confirming the dematerialization and rematerialization of securities.
Read the summary - Low impact
Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary, Compliance Officer, KMP effective April 9, 2026
Cohance Lifesciences Limited has appointed Mr. Sisir K. Mishra as Company Secretary, Compliance Officer, and Key Managerial Personnel. The appointment is effective from April 9, 2026. Mr. Mishra brings over two decades of experience in corporate secretarial and governance roles.
Read the summary - Low impact
Cohance Lifesciences Closes Trading Window from April 1 for FY26 Audited Results
Cohance Lifesciences will close its trading window from April 1, 2026. The window will reopen 48 hours after the announcement of audited financial results for the quarter and year ending March 31, 2026. The date for the board meeting to approve these results will be announced later.
Read the summary - Low impact
Cohance Lifesciences Grants 1,98,711 Stock Options Under ESOP 2023
Cohance Lifesciences has granted 1,98,711 stock options to eligible employees under its ESOP 2023. These options can be exercised within three years of vesting, which occurs between one to ten years from the grant date.
Read the summary - Low impact
Cohance Lifesciences to attend Investec CDMO Day in Hyderabad on March 13, 2026
Cohance Lifesciences Limited will attend the Investec CDMO Day roadshow in Hyderabad on March 13, 2026. Management will participate in group interactions. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
Cohance Lifesciences to Attend IIFL & Kotak Conferences on Feb 25-26
Cohance Lifesciences Limited will attend the IIFL Entrepreneurial India Conference on February 25, 2026, and the Kotak Chasing Growth Conference on February 26, 2026. The company will engage in group and one-on-one meetings with investors. No unpublished price-sensitive information will be disclosed.
Read the summary - Medium impact
Cohance Lifesciences Releases Q3 FY26 Earnings Call Transcript
Cohance Lifesciences released the transcript of its Q3 FY26 earnings call. The company acknowledged performance below expectations due to portfolio mix and timing factors. While FY26 revenue declined, management reiterated commitment to the USD 1 billion sales target for FY30, anticipating FY27 growth.
Read the summary - Medium impact
Cohance Lifesciences Q3 FY26 Results: Total Income at ₹1462.95 Crore, Net Profit at ₹194.15 Crore
Cohance Lifesciences reported unaudited financial results for the quarter and nine months ended December 31, 2025. Total income for nine months was ₹1462.95 crore. Net profit after tax for nine months was ₹194.15 crore. Quarter ended December 31, 2025, saw total income of ₹481.58 crore and net profit of ₹47.29 crore.
Read the summary - Low impact
Cohance Lifesciences Releases Audio Recording of Q3 FY26 Earnings Call
Cohance Lifesciences has released the audio recording of its conference call for the quarter and nine months ended December 31, 2025. The call took place on February 12, 2026, and the recording is accessible on the company's website.
Read the summary - Medium impact
Cohance Lifesciences Q3FY26 Investor Presentation Highlights Transition Phase
Cohance Lifesciences reports a transition phase for FY26 with revised revenue guidance to a double-digit decline. The company achieved EcoVadis Gold for sustainability. 9MFY26 revenue was ₹16.5 billion, with free cash flow of ₹1.75 billion. Investments continue in R&D and capacity expansion, with an expected return to growth in FY27.
Read the summary - Medium impact
Cohance Lifesciences Q3FY26 Revenue Declines 19.5% to ₹544.6 Crore; 9MFY26 Revenue Down 6.7%
Cohance Lifesciences reported Q3FY26 revenue of ₹544.6 crore, a 19.5% decrease. 9MFY26 revenue was ₹1,649.4 crore, down 6.7%. Gross margins improved to 72.8% for 9MFY26. Adjusted EBITDA for 9MFY26 was ₹347.7 crore, a 43% decline. The company cited customer inventory adjustments and biotech funding cycles for the performance.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio